Freedman, Mark S.
Coyle, Patricia K.
Hellwig, Kerstin
Singer, Barry
Wynn, Daniel
Weinstock-Guttman, Bianca
Markovic-Plese, Silva
Galazka, Andrew
Dangond, Fernando
Korich, Julie
Reder, Anthony T.
Funding for this research was provided by:
EMD Serono
Article History
Received: 26 July 2023
Accepted: 6 November 2023
First Online: 11 January 2024
Declarations
:
: Mark S. Freedman has received honoraria or consultation fees from Actelion (Janssen/J&J), Alexion/Astra Zeneca, Biogen, Celgene (BMS), Find Therapeutics, Hoffmann La Roche, Horizon Therapeutics, Merck and Co, Novartis, Sandoz, Sanofi-Genzyme, and Teva Canada Innovation; has received research support unrelated to this study from Sanofi-Genzyme Canada, Hoffman-La Roche, and Merck Healthcare KGaA, Darmstadt, Germany; was a member of a company advisory board, board of directors, or other similar group for Actelion (Janssen/J&J), Alexion/Astra Zeneca, Atara Biotherapeutics, Bayer Healthcare, Biogen Idec, Celgene (BMS), Horizon Therapeutics, Hoffman La-Roche, Merck Healthcare KGaA, Darmstadt, Germany, Novartis, Sanofi-Genzyme, and Teva Canada Innovation; and has been a participant in a company sponsored speaker’s bureau for Sanofi-Genzyme and Merck Healthcare KGaA, Darmstadt, Germany). Patricia K. Coyle declares receiving consulting & nonbranded speaker fees from Accordant, Biogen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Horizon Therapeutics, Janssen, Mylan, Novartis, Sanofi Genzyme, TG Therapeutics, and Viela Bio; and research support from Actelion, Alkermes, Celgene, CorEvitas LLC, Genentech/Roche, MedDay, NINDS, Novartis, and Sanofi Genzyme. Kerstin Hellwig has received consulting fees, fees for non-CME services, and speaker’s bureau from Bayer, Biogen, Merck and Co, Novartis, Roche, Sanofi, and Teva. Barry Singer has received research support from AbbVie, Biogen, Greenwich Biosciences, Novartis, and Sanofi Genzyme; and consulting and/or speaking fees from AbbVie, Alexion, Biogen, Bristol Myers Squibb, Cigna, Merck Healthcare KGaA, Darmstadt, Germany, Janssen, Genentech, Greenwich Biosciences, Horizon, Novartis, Octave Bioscience, Roche, Sanofi Genzyme, and TG Therapeutics. Daniel Wynn – employer has received research funding, speaker fees, or served as expert witness for AbbVie, Adamas, Allergan, ANI Pharma, Avanir, Banner Life, Biogen, Bristol Myers Squibb, Chugai, Eli Lilly, Merck Healthcare KGaA, Darmstadt, Germany, Genentech, GW Therapeutics, Immunic, InnoCare, Janssen, Jazz Pharmaceuticals, Mallinckrodt, MAPI Therapeutics, Mylan, National MS Society, Novartis, SanBio, Sanofi Genzyme, UCB Biopharma, Viela Bio, Teva Pharmaceuticals, and TG Therapeutics. Bianca Weinstock-Guttman has participated in speaker’s bureaus and/or served as a consultant for Bayer, Biogen, Celgene/Bristol Meyers Squibb, Merck Healthcare KGaA, Genentech, Janssen and Horizon, Novartis, and Sanofi Genzyme; has received grant/research support from the agencies listed in the previous sentence; and serves in the editorial board for BMJ Neurology, Children, CNS Drugs, Frontiers Epidemiology, and MS International. Silva Markovic-Plese has received grant research support from Bristol Myers Squibb and honoraria from Genentech and Janssen Pharmaceuticals for participation in editorial boards. Andrew Galazka has received consulting fees from the healthcare business of Merck Healthcare KGaA, Darmstadt, Germany. Fernando Dangond was formerly an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, and is currently an employee of Bristol Myers Squibb. Julie Korich is an employee of EMD Serono Inc., Rockland, MA, USA, an affiliate of Merck KGaA. Anthony T. Reder has received consulting fees from Acorda, Bayer, Biogen, BMS, Merck Healthcare KGaA, Genentech, Genzyme, Novartis, Pfizer, Mallinckrodt (formerly Questcor), Sanofi, and Teva Pharmaceuticals.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.